Genelux Reports Q3 Net Loss, Exceeding Expectations in Immuno-Oncology

Genelux Corporation, a biopharmaceutical company, reported a Q3 net loss that beat expectations. The company is focused on developing oncolytic viral immunotherapies for solid tumor types, with its lead product candidate, Olvi-Vec, a modified strain of the vaccinia virus intended to selectively kill tumor cells and induce an immune response. The company's portfolio includes oncolytic vaccinia immunotherapy clinical candidates.